Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longitudinal phase 3 study.

You may be able to join if

• 1. Sexually active postmenopausal women with breast cancer and ongoing adjuvant antiestrogen treatment with aromatase inhibitors who are willing to participate in the study and give their written consent. 2. Postmenopausal women with at least 12 months of spontaneous amenorrhea, or women who have had surgical bilateral oophorectomy at least 6 weeks ago, or level of follicle stimulating hormone (FSH) > 40 mIU/mL. 3. Have a vaginal pH > 5.0 at screening. 4. Have ≤ 5% superficial cells in vaginal smear cytology at screening. 5. Have estradiol levels below the detection level, < 20 pmol/l. 6. Have one moderate to severe vulvovaginal atrophy symptom on the FACT-B scale that has been identified by the subject as being the most bothersome to her. 7. Be judged by the principal investigator as being in otherwise good health. The medical evaluation findings must include: a. A normal or clinically non-significant finding at physical examination. b. A mean sitting systolic blood pressure ≤150 mm Hg and diastolic blood pressure ≤90 mm Hg at screening. c. A normal or clinically non-significant finding at gynaecological examination. d. A normal mammography that has been performed within 36 months prior to initial dose of study medication. e. Laboratory values within normal limits or with non-significant deviations from normal values. 8. Have an endometrial thickness of < 4 mm as determined by vaginal ultrasonography, in women with an intact uterus.